Evidence map›Paper›PMID 33097973›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2021

Impact of chemerin, lipid profile, and insulin resistance on disease parameters in patients with multiple sclerosis.

Asli Koskderelioglu, Muhtesem Gedizlioglu, Neslihan Eskut, Pinar Tamer, Gizem Yalcin, Giray Bozkaya

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Is Obesity a Modifiable Risk Factor in Multiple Sclerosis? Mechanistic Insights into Neuroinflammation and Oxidative Damage.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  3. Article
  4. Review
  5. Adipokines as Immune Cell Modulators in Multiple Sclerosis.International journal of molecular sciences · 2021
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Asli KoskdereliogluDepartment of Neurology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Saim Cikrikci cad. No:59 Karabaglar, 35170, Izmir, Turkey. copura@gmail.com.ORCID http://orcid.org/0000-0002-7828-6382
Muhtesem GedizliogluDepartment of Neurology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Saim Cikrikci cad. No:59 Karabaglar, 35170, Izmir, Turkey.
Neslihan EskutDepartment of Neurology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Saim Cikrikci cad. No:59 Karabaglar, 35170, Izmir, Turkey.
Pinar TamerDepartment of Neurology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Saim Cikrikci cad. No:59 Karabaglar, 35170, Izmir, Turkey.
Gizem YalcinDepartment of Biochemistry, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey.
Giray BozkayaDepartment of Biochemistry, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey.
Izmir University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPlasma chemerin, which has chemotactic and adipogenic functions, is increased in several inflammatory diseases. However, its relationship with multiple sclerosis (MS) has not been explored yet. In this study, we aimed to determine chemerin levels and their possible role in MS.

methodsChemerin serum concentrations were evaluated by using ELISA kit in 91 clinically definite MS patients and 52 healthy controls. The mean serum chemerin, insulin, and cholesterol levels were compared. Patients were divided into two groups according to the body mass index (BMI), and the relationships between clinical and metabolic parameters were evaluated.

resultsSerum chemerin levels were 10.46 ± 1.65 ng/mL in MS patients and 10.26 ± 2.14 ng/mL in the control group. No significant difference was found between patients and controls (p = 0.55). We found no difference regarding age, gender, and BMI between two groups (p = 0.053, p = 0.54, p = 0.41). However, female patients with MS had higher chemerin levels than male patients. There were no associations between serum chemerin levels and EDSS score, annualized relapse rate, BMI, insulin resistance, and serum cholesterol levels in MS patients.

conclusionIn this study, we aimed to determine serum chemerin levels in patients with MS. However, in our study, there was no significant difference between serum chemerin levels of MS patients and healthy controls'. Additionally, chemerin levels were not associated with other metabolic parameters, as well as cognitive dysfunction. Further studies are needed to evaluate the role of chemerin in MS patients.

Indexed as

Insulin ResistanceMultiple SclerosisBody Mass IndexChemokinesFemaleHumansIntercellular Signaling Peptides and ProteinsLipidsMaleObesityChemokinesIntercellular Signaling Peptides and ProteinsLipidsRARRES2 protein, humanChemerinDisease activityMultiple sclerosisObesity

Identifiers

PMID33097973
OpenAlexW3093635347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.